MX2010005070A - Derivados de piridazinona como inhibidores de parp. - Google Patents
Derivados de piridazinona como inhibidores de parp.Info
- Publication number
- MX2010005070A MX2010005070A MX2010005070A MX2010005070A MX2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A MX 2010005070 A MX2010005070 A MX 2010005070A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- parp inhibitors
- cancer
- pyridazinone derivatives
- treatment
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010057430 Retinal injury Diseases 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 230000037380 skin damage Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0722401A GB0722401D0 (en) | 2007-11-15 | 2007-11-15 | Therapeutic compounds |
| GB0816707A GB0816707D0 (en) | 2008-09-12 | 2008-09-12 | Therapeutic compounds |
| PCT/GB2008/051063 WO2009063244A1 (en) | 2007-11-15 | 2008-11-14 | Pyridazinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005070A true MX2010005070A (es) | 2010-05-24 |
Family
ID=40427149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005070A MX2010005070A (es) | 2007-11-15 | 2008-11-14 | Derivados de piridazinona como inhibidores de parp. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8268827B2 (enExample) |
| EP (1) | EP2220073B1 (enExample) |
| JP (1) | JP5758630B2 (enExample) |
| KR (1) | KR101641596B1 (enExample) |
| CN (1) | CN101855221B (enExample) |
| AU (1) | AU2008322676B9 (enExample) |
| CA (1) | CA2704714C (enExample) |
| ES (1) | ES2524787T3 (enExample) |
| IL (1) | IL205142A (enExample) |
| MX (1) | MX2010005070A (enExample) |
| NZ (1) | NZ585395A (enExample) |
| RU (1) | RU2490265C2 (enExample) |
| WO (1) | WO2009063244A1 (enExample) |
| ZA (1) | ZA201002466B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822476B2 (en) * | 2009-04-02 | 2014-09-02 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| US9090568B2 (en) * | 2011-03-14 | 2015-07-28 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
| ES2871052T3 (es) | 2011-05-31 | 2021-10-28 | Rakovina Therapeutics Inc | Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa |
| US9328111B2 (en) | 2011-12-31 | 2016-05-03 | Beigene Ltd. | Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors |
| SI2797921T1 (en) | 2011-12-31 | 2018-01-31 | Beigene, Ltd. | Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors |
| KR20220137154A (ko) | 2012-01-20 | 2022-10-11 | 데니스 엠. 브라운 | 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도 |
| SG11201408679XA (en) | 2012-06-26 | 2015-01-29 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| MA38080A1 (fr) * | 2012-12-31 | 2018-02-28 | Cadila Healthcare Ltd | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
| US10106501B2 (en) * | 2015-06-09 | 2018-10-23 | Abbvie Inc. | Nuclear receptor modulators |
| EA033679B1 (ru) * | 2015-09-02 | 2019-11-15 | Glaxosmithkline Ip No 2 Ltd | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| US10246469B2 (en) | 2015-10-01 | 2019-04-02 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| KR102030016B1 (ko) | 2016-09-05 | 2019-10-08 | 충남대학교산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR102007135B1 (ko) | 2017-03-20 | 2019-08-02 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
| CN108383837B (zh) * | 2018-02-09 | 2020-08-11 | 福建医科大学 | 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用 |
| WO2019212946A1 (en) | 2018-04-30 | 2019-11-07 | Ribon Therapeutics Inc. | Screening methods for parp modulators |
| HUE062096T2 (hu) * | 2018-04-30 | 2023-09-28 | Ribon Therapeutics Inc | Piridazinonok PARP7-inhibitorokként |
| KR102017115B1 (ko) | 2018-05-15 | 2019-09-02 | 충남대학교산학협력단 | 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| CN110818908B (zh) * | 2019-08-29 | 2021-12-17 | 杭州市富阳区浙工大银湖创新创业研究院 | 一种用于检测氧化气体的金属有机骨架材料的制备方法 |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20240190844A1 (en) * | 2019-10-30 | 2024-06-13 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| AU2020375821A1 (en) | 2019-10-30 | 2022-06-02 | Ribon Therapeutics, Inc. | Pyridazinones as PARP7 inhibitors |
| CA3158807A1 (en) | 2019-10-30 | 2021-05-06 | Digmbio. Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| EP4139298A4 (en) | 2020-04-21 | 2024-05-22 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| AU2020444056A1 (en) | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
| WO2021224186A1 (en) * | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| CN117425648A (zh) * | 2021-03-12 | 2024-01-19 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CA3212583A1 (en) | 2021-03-27 | 2022-10-06 | Daniel Gooding | Compositions having improved bioavailability of therapeutics |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| CN117751108A (zh) * | 2021-07-21 | 2024-03-22 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| JP2024528021A (ja) * | 2021-07-29 | 2024-07-26 | 上海齊魯制藥研究中心有限公司 | 新規なｐａｒｐ７阻害剤及びその使用 |
| CN117279907A (zh) * | 2021-08-06 | 2023-12-22 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116375688B (zh) * | 2021-12-23 | 2025-04-11 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| CA3245873A1 (en) * | 2022-03-14 | 2023-09-21 | Trx Biosciences Ltd | Compositions with improved bioavailability of therapeutic agents and their uses |
| JP7763538B2 (ja) * | 2022-04-01 | 2025-11-04 | 諾沃斯達薬業（上海）有限公司 | Ｐａｒｐ７阻害剤及びその使用 |
| JP2025534359A (ja) * | 2022-09-30 | 2025-10-15 | アズカラ セラピューティクス インク | ピリダジン－３（２ｈ）－オンおよびピリジン－２（１ｈ）－オンのＰＡＲＰ阻害化合物 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025087383A1 (zh) * | 2023-10-26 | 2025-05-01 | 深圳众格生物科技有限公司 | 作为parp7抑制剂的化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
| KR100804564B1 (ko) | 2000-10-30 | 2008-02-20 | 쿠도스 파마슈티칼스 리미티드 | 프탈라지논 유도체 |
| EP1397350B1 (en) | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| ES2357057T3 (es) | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| MXPA05010081A (es) * | 2003-03-24 | 2005-11-23 | Hoffmann La Roche | Bencil-piridazinonas como inhibidores de transcriptasa inversa. |
| MXPA06009701A (es) | 2004-02-26 | 2007-03-26 | Inotek Pharmaceuticals Corp | Derivados de isoquinolina y metodos de uso de los mismos. |
| JP4627315B2 (ja) | 2004-03-23 | 2011-02-09 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体 |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| JP2007532592A (ja) * | 2004-04-15 | 2007-11-15 | エフ．ホフマン−ラ ロシュ アーゲー | ピリダジノン化合物の製造方法 |
| WO2006021801A1 (en) | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| HRP20100633T1 (hr) | 2005-07-21 | 2011-01-31 | F. Hoffmann - La Roche Ag | Derivati piridazinona kao agonisti receptora tiroidnih hormona |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| PH12012501544A1 (en) * | 2006-12-28 | 2024-06-03 | Abbvie Inc | Inhibitors of poly (adp-ribose) polymerase |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
-
2008
- 2008-11-14 KR KR1020107013113A patent/KR101641596B1/ko active Active
- 2008-11-14 EP EP08850429.5A patent/EP2220073B1/en active Active
- 2008-11-14 CA CA2704714A patent/CA2704714C/en active Active
- 2008-11-14 JP JP2010533666A patent/JP5758630B2/ja active Active
- 2008-11-14 MX MX2010005070A patent/MX2010005070A/es active IP Right Grant
- 2008-11-14 CN CN2008801155905A patent/CN101855221B/zh active Active
- 2008-11-14 WO PCT/GB2008/051063 patent/WO2009063244A1/en not_active Ceased
- 2008-11-14 ES ES08850429.5T patent/ES2524787T3/es active Active
- 2008-11-14 US US12/739,262 patent/US8268827B2/en active Active
- 2008-11-14 NZ NZ585395A patent/NZ585395A/en unknown
- 2008-11-14 RU RU2010123874/04A patent/RU2490265C2/ru active
- 2008-11-14 AU AU2008322676A patent/AU2008322676B9/en active Active
-
2010
- 2010-04-08 ZA ZA2010/02466A patent/ZA201002466B/en unknown
- 2010-04-15 IL IL205142A patent/IL205142A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201002466B (en) | 2010-12-29 |
| IL205142A0 (en) | 2010-11-30 |
| US20100261709A1 (en) | 2010-10-14 |
| CN101855221A (zh) | 2010-10-06 |
| ES2524787T3 (es) | 2014-12-12 |
| RU2490265C2 (ru) | 2013-08-20 |
| KR20100087220A (ko) | 2010-08-03 |
| US8268827B2 (en) | 2012-09-18 |
| JP5758630B2 (ja) | 2015-08-05 |
| AU2008322676A1 (en) | 2009-05-22 |
| WO2009063244A1 (en) | 2009-05-22 |
| EP2220073A1 (en) | 2010-08-25 |
| JP2011503166A (ja) | 2011-01-27 |
| AU2008322676B9 (en) | 2014-03-27 |
| CA2704714A1 (en) | 2009-05-22 |
| BRPI0820236A2 (pt) | 2015-06-16 |
| RU2010123874A (ru) | 2011-12-20 |
| CA2704714C (en) | 2018-12-04 |
| CN101855221B (zh) | 2013-10-30 |
| KR101641596B1 (ko) | 2016-07-21 |
| NZ585395A (en) | 2012-03-30 |
| IL205142A (en) | 2014-09-30 |
| AU2008322676B2 (en) | 2013-12-05 |
| EP2220073B1 (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005070A (es) | Derivados de piridazinona como inhibidores de parp. | |
| WO2007138351A3 (en) | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) | |
| MX2009007200A (es) | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). | |
| MY147789A (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| WO2008017883A3 (en) | 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) | |
| WO2008103277A3 (en) | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors | |
| WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
| TW200942527A (en) | Pyridazine derivatives as factor XIa inhibitors | |
| WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
| MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
| WO2010021918A8 (en) | Compounds as kinase inhibitors | |
| EP2012780A4 (en) | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists | |
| WO2007076228A3 (en) | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders | |
| WO2008086128A3 (en) | Aminopyrazole kinase inhibitors | |
| WO2008084067A3 (en) | Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives | |
| TH141815A (th) | สารยับยั้งไคเนสซึ่งมีโพรไฟล์ด้านความปลอดภัยของ cyp ที่ดีขึ้น | |
| WO2009005469A3 (en) | The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |